Eli Lilly and
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $19,799,000 | $19,292,000 | $17,600,800 | $15,557,700 |
Gross Profit | 16,222,000 | 16,408,300 | 14,592,500 | 13,109,900 |
EBITDA | 9,359,000 | 8,388,000 | 7,882,000 | 7,503,900 |
EBIT | 8,850,000 | 8,235,800 | 7,412,000 | 7,025,400 |
Net Income | 7,396,000 | 6,636,000 | 5,582,500 | 5,660,500 |
Net Change In Cash | 19,799,000 | 19,292,000 | 17,600,800 | 15,557,700 |
Free Cash Flow | 3,007,000 | 677,900 | 8,612,000 | 1,283,000 |
Cash | 5,282,000 | 7,163,000 | 9,791,900 | 3,375,900 |
Basic Shares | 895,900 | 898,002 | 898,800 | 899,793 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $65,179,000 | $45,042,700 | $34,124,100 | $28,541,400 |
Gross Profit | 54,615,000 | 36,624,400 | 27,041,900 | 21,911,600 |
EBITDA | 27,936,500 | 15,227,600 | 8,567,800 | 8,660,500 |
EBIT | 26,373,000 | 13,461,000 | 7,040,500 | 7,138,000 |
Net Income | 20,638,300 | 10,590,000 | 5,240,400 | 6,244,800 |
Net Change In Cash | 65,179,000 | 45,042,700 | 34,124,100 | 28,541,400 |
Cost of Revenue | -1,583,900 | |||
Free Cash Flow | 8,972,000 | 414,300 | -3,152,000 | 4,600,400 |
Cash | 7,163,000 | 3,268,400 | 2,818,600 | 2,067,000 |
Basic Shares | 898,002 | 904,059 | 903,284 | 950,182 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $8.55 |
2025-12-31 | $7.54 |
2025-09-30 | $7.02 |
2025-06-30 | $6.29 |